Regeneron Pharmaceuticals, Inc. REGN
NASDAQ · United States · Health Technology
$758.27+7.76 (+1.03%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
These ratios divide the lines in the statements below by the current price; both inputs of every value are visible on this page. The P/E on the overview comes from the same calculation. P/E and P/S are left blank for loss-making companies or where revenue is not reported. Not investment advice.
| LTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | $15.53B | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| Revenue growth (YoY) | — | +1.0% | +8.3% | +7.8% | -24.3% | — |
| Operating expenses | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating Income | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating margin | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| EBITDA | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Pre-tax income | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Income tax | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Net Income | $4.33B | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| Net margin | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted EPS | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted shares | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| LTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & equivalents | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Current Assets | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Assets | $41.73B | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B |
| Total Current Liabilities |
| LTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash from Operations | $4.68B | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B |
| Capital expenditure | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Free cash flow | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Investing |
Taken from the company's own 10-K and 10-Q filings via the SEC's XBRL data service. The "LTM" column is the last completed fiscal year plus the current year to date, minus the same period a year earlier. Lines a company tags with a non-standard label are left blank rather than filled with an approximation. Not investment advice.
| MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| Total Liabilities | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Equity | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| Cash from Financing | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |